drugset / Trial / NCT06528496
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
Timeline
- Start
- 2024-07-22
- Primary completion
- 2029-07-22
- Completion
- 2029-07-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Ifosfamide | Small molecule | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Naxitamab | Monoclonal antibody | — | — |
| Subject | Temozolomide | Small molecule | — | Intravenous |
| Subject | Topotecan | Small molecule | — | — |
| Subject | Vincristine | Small molecule | — | — |
| Subject | sargramostim | Protein / enzyme biologic | — | — |